The role of the CEO is subordinate to the board of directors and the CEOs’ main task is to carry out the Company’s ongoing management and the daily activities of the Company. The rules of procedure of the board of directors and the instructions for the CEO stipulate which matters the board shall resolve upon, and which matters fall within the CEOs’ area of responsibility.
Furthermore, the CEO is responsible for preparing reports and necessary information for decision-making prior to board meetings and presents the material at board meetings.
The senior management currently consists of the CEO, CFO, Head of Regulatory Affairs, Head of Clinical Development, Head of Research and CMC, CMO, CSO, CCO, Head of Medical Relations, Head of IR and Head of Pharmacovigilance.
|Name||Position||Member of senior management since||Employed in the Company since||Holdings in Oncopeptides (1)|
|Bengt Gustavsson||Head of Medical Relations||2017||2017||600||–||116,995|
|Christian Jacques||CSO||2018||2018 (2)||–||–||223,280|
|Elisabeth Augustsson||Head of Regulatory Affairs||2015||2015 (2)||–||–||93,117|
|Eva Nordström||Head of Clinical Development||2012||2012||150,200||33||117,283|
|Fredrik Lehmann||Head of Research and CMC||2008||2008||1,000||50||82,017|
|Johan Harmenberg||CMO||2012||2012 (2)||5,000||160||82,806|
|Rein Piir||Head of IR||2016||2016 (2)||2,500||–||89,917|
|Thomas Bradley||Head of Pharmacovigilance||2017||2018 (2)||–||–||70,387|
|(1) Refers to shares (“SH”), employee options (“EO”) and options (“O”) held in their own name as well as by affiliated natural and legal persons. Employee options that are vested in accordance with prevailing terms and conditions each entitle to the subscription of 900 shares per option in Company. The options (“O”) entitles to one share per option in accordance with existing terms. For terms, please read under Corporate Governance – Remuneration.|
|(2) The assignment is carried out on a consultancy basis.|